What are your top takeaways in Thoracic Cancers from ASCO 2022?

1. Abst 8502 - Quality metrics and survival after lung cancer surgery: More efficient work-ups and consistently high quality resections will likely do more to improve lung cancer survival than any adjuvant or neo-adjuvant therapy we can come up with. This is low-hanging, low-cost fruit.

2. Abst 9007...

1. KRYSTAL-1: This was a phase II trial of adagrasib in patients with advanced KRAS G12C NSCLC. In 112 patients who had prior immunotherapy and prior chemotherapy, the response rate was 43% with a median duration of response of 8.5 months. While sotorasib is an approved agent, adagrasib could be ano...

1. Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis.
This validates the lack of OS benefit in giving PDL1 high patients combination therapy, and validates the ...

1. Plenary TDXD presentation: Impactful not only for breast cancer, and not even just for all HER2+ cancers, but for our understanding of ADCs. ADCs may replace cytotoxic chemotherapy for many patients. I think of them as "slightly targeted chemotherapy" -- advances in efficacy of chemo are badly ne...

1. SKYSCRAPER-02: Press release ahead of the meeting indicated the study didn't meet its endpoint. Data presented showed survival curves essentially overlapping, not even a numerical trend to favor the investigational arm of tiragolumab added to chemoimmunotherapy as 1st line treatment for extensive...